Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Dean C. Pavlick"'
Autor:
Chien-Yu Lin, Sheng-Huan Wei, Yi-Lin Chen, Chung-Ta Lee, Shang-Yin Wu, Chung-Liang Ho, Dean C. Pavlick, Po-Lan Su, Chien-Chung Lin
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Telisotuzumab vedotin is a MET-targeting antibody–drug conjugate that has demonstrated a good treatment response in patients with EGFR wild-type MET-overexpressing non-squamous non-small cell lung cancer. However, patients have been reported to acq
Externí odkaz:
https://doaj.org/article/c5d82a14666246079097088647b395c1
Autor:
Zhenfang Du, Benjamin P. Brown, Soyeon Kim, Donna Ferguson, Dean C. Pavlick, Gowtham Jayakumaran, Ryma Benayed, Jean-Nicolas Gallant, Yun-Kai Zhang, Yingjun Yan, Monica Red-Brewer, Siraj M. Ali, Alexa B. Schrock, Ahmet Zehir, Marc Ladanyi, Adam W. Smith, Jens Meiler, Christine M. Lovly
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
An EGFR mutant with kinase domain duplication (EGFR-KDD) was previously identified in an index patient, but the functional and therapeutic implications remain unclear. Here, the authors show that KDD occurs in other ErbB receptors in multiple cancers
Externí odkaz:
https://doaj.org/article/b948db7f0a2649d5908bbadfe529545e
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BRAF fusions are rare driver oncogenes in non-small cell lung cancer (NSCLC). Similar with BRAF V600E mutation, it could also activate the MAPK signaling pathway. There are a few case reports which had indicated the potential response to BRAF inhibit
Externí odkaz:
https://doaj.org/article/21c1ff32245b4559ad40e5ea9d66889c
Autor:
Coren A. Milbury, James Creeden, Wai-Ki Yip, David L. Smith, Varun Pattani, Kristi Maxwell, Bethany Sawchyn, Ole Gjoerup, Wei Meng, Joel Skoletsky, Alvin D. Concepcion, Yanhua Tang, Xiaobo Bai, Ninad Dewal, Pei Ma, Shannon T. Bailey, James Thornton, Dean C. Pavlick, Garrett M. Frampton, Daniel Lieber, Jared White, Christine Burns, Christine Vietz
Publikováno v:
PLoS ONE, Vol 17, Iss 3 (2022)
FoundationOne®CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-approved companion diagnostic test to identify patients who may benefit from treatment in accordance with the approved therapeutic product labeling for 28 drug ther
Externí odkaz:
https://doaj.org/article/c077dd424a014a30b87dd38f621e7d50
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Introduction Several studies have shown clinical outcomes data that support the use of CD274 (PD-L1) copy-number (CN) gains and/or losses as a biomarker for immune checkpoint inhibitor (ICPI). Here, we present the landscape of CD274 CN changes across
Externí odkaz:
https://doaj.org/article/c9754252d8e140ad96c8184de22aa3e4
Autor:
Daniel J, Zaccarini, Abirami, Sivapiragasam, Ethan, Sokol, Richard S P, Huang, Dean C, Pavlick, Tyler, Janovitz, Michele R, Nasr, Jeffrey S, Ross
Publikováno v:
Applied Immunohistochemistry & Molecular Morphology. 30:609-613
Oncocytic histologic features can be seen in a variety of salivary gland carcinomas. We performed a comprehensive molecular profiling of 15 salivary gland malignancies with oncocytic features (diagnosed as oncocytic carcinoma, carcinoma NOS with onco
Autor:
Lee A. Albacker, Priti S. Hegde, Garrett M. Frampton, Brian M. Alexander, Naiyer A. Rizvi, Leah A. Comment, David Fabrizio, Gaurav Singal, Alan Braly, Jay A. Moore, Dean C. Pavlick, Ethan S. Sokol, Virginia Fisher, Gerald Li, Max Minker, Ameet Guria, Nora Sanchez, Radwa Sharaf, Dexter X. Jin, Karthikeyan Murugesan, Meagan Montesion
Somatic HLA-I LOH is associated with decreased durable clinical benefit and progression free survival in ICI-treated NSCLC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25ae8eba790bd7e6d70baa335276b460
https://doi.org/10.1158/2159-8290.22535725.v1
https://doi.org/10.1158/2159-8290.22535725.v1
Autor:
Lee A. Albacker, Priti S. Hegde, Garrett M. Frampton, Brian M. Alexander, Naiyer A. Rizvi, Leah A. Comment, David Fabrizio, Gaurav Singal, Alan Braly, Jay A. Moore, Dean C. Pavlick, Ethan S. Sokol, Virginia Fisher, Gerald Li, Max Minker, Ameet Guria, Nora Sanchez, Radwa Sharaf, Dexter X. Jin, Karthikeyan Murugesan, Meagan Montesion
Neoantigen presentation arises as a result of tumor-specific mutations and is a critical component of immune surveillance that can be abrogated by somatic LOH of the human leukocyte antigen class I (HLA-I) locus. To understand the role of HLA-I LOH i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e82d91644d24da5d493cb0d66e86e71
https://doi.org/10.1158/2159-8290.c.6547924.v1
https://doi.org/10.1158/2159-8290.c.6547924.v1
Autor:
Lee A. Albacker, Priti S. Hegde, Garrett M. Frampton, Brian M. Alexander, Naiyer A. Rizvi, Leah A. Comment, David Fabrizio, Gaurav Singal, Alan Braly, Jay A. Moore, Dean C. Pavlick, Ethan S. Sokol, Virginia Fisher, Gerald Li, Max Minker, Ameet Guria, Nora Sanchez, Radwa Sharaf, Dexter X. Jin, Karthikeyan Murugesan, Meagan Montesion
Characteristics of patients in the real-world clinico-genomic cohort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d04d6516cd719ccacceafa013677769
https://doi.org/10.1158/2159-8290.22535713.v1
https://doi.org/10.1158/2159-8290.22535713.v1
Autor:
Marni B Tierno, Kali C Dougherty, Erica Gornstein, Dean C Pavlick, Alexa Schrock, Geoff R Oxnard
Publikováno v:
Cancer Research. 82:P3-07
Background Detection of pathogenic GVs in patients with BC has implications for both patients and their family members. Management options such as increased surveillance, chemoprevention, and surgical prophylaxis are available to GV carriers. Beyond